BACKGROUND: HIV amongst injecting drug users (IDUs) has been described in Kabul but little data exists for other Afghan cities. We assessed HIV, hepatitis B virus (HBV), and C virus (HCV) prevalence and associated risk behaviours amongst IDUs in Hirat, Jalalabad, and Mazar-i-Sharif, Afghanistan. METHODS: Consented participants reporting injecting drugs within the previous 6 months completed interviewer-administered questionnaires and testing for HIV, hepatitis C antibody (HCV Ab), and hepatitis B surface antigen (HBsAg). Logistic regression was used to determine characteristics associated with each infection. RESULTS: Of 623 participants, most (98.7%) were male. Prevalence of HIV, HCV, and HBV was 1.8% (95% CI: 0.88-3.2), 36.0% (95% CI: 33-41), and 5.8% (95% CI: 3.9-7.6), respectively. All HIV cases and highest HCV prevalence were detected in Hirat; HBV prevalence was highest in Jalalabad. Amongst male IDUs, 62.9% had been imprisoned, of whom 17.2% (n=66) injected in prison. High risk behaviours were common; 30.2% reported needle sharing in the last 6 months, 23.1% reported sex with another male, and 50.4% reported paying females for sex. Behaviours varied significantly by site; generally, Hirat participants reported fewer sexual risk behaviours. Sex with other males was negatively associated with both HBV and HCV in multivariate logistic regression analysis; no injecting behaviours were associated with both HBV and HCV. CONCLUSIONS: Whilst HIV prevalence is low, HCV prevalence and high risk behaviours were common in these populations. Regional variations should be considered in programming to prevent transmission of HIV and viral hepatitis amongst IDUs in Afghanistan.
BACKGROUND: HIV amongst injecting drug users (IDUs) has been described in Kabul but little data exists for other Afghan cities. We assessed HIV, hepatitis B virus (HBV), and C virus (HCV) prevalence and associated risk behaviours amongst IDUs in Hirat, Jalalabad, and Mazar-i-Sharif, Afghanistan. METHODS: Consented participants reporting injecting drugs within the previous 6 months completed interviewer-administered questionnaires and testing for HIV, hepatitis C antibody (HCV Ab), and hepatitis B surface antigen (HBsAg). Logistic regression was used to determine characteristics associated with each infection. RESULTS: Of 623 participants, most (98.7%) were male. Prevalence of HIV, HCV, and HBV was 1.8% (95% CI: 0.88-3.2), 36.0% (95% CI: 33-41), and 5.8% (95% CI: 3.9-7.6), respectively. All HIV cases and highest HCV prevalence were detected in Hirat; HBV prevalence was highest in Jalalabad. Amongst male IDUs, 62.9% had been imprisoned, of whom 17.2% (n=66) injected in prison. High risk behaviours were common; 30.2% reported needle sharing in the last 6 months, 23.1% reported sex with another male, and 50.4% reported paying females for sex. Behaviours varied significantly by site; generally, Hirat participants reported fewer sexual risk behaviours. Sex with other males was negatively associated with both HBV and HCV in multivariate logistic regression analysis; no injecting behaviours were associated with both HBV and HCV. CONCLUSIONS: Whilst HIV prevalence is low, HCV prevalence and high risk behaviours were common in these populations. Regional variations should be considered in programming to prevent transmission of HIV and viral hepatitis amongst IDUs in Afghanistan.
Authors: Jose L Sanchez; Catherine S Todd; Christian T Bautista; Boulos A E Botros; Mumtoz M Khakimov; Guzal M Giyasova; Shavkat K Yakubov; Mukhabat A Abdulaeva; Maghdi D Saad; Ross R Graham; Jean K Carr; Kenneth C Earhart Journal: Drug Alcohol Depend Date: 2006-04 Impact factor: 4.492
Authors: Julie A Stachowiak; Farida K Tishkova; Steffanie A Strathdee; Mark A Stibich; Alisher Latypov; Vladimir Mogilnii; Chris Beyrer Journal: Drug Alcohol Depend Date: 2006-04 Impact factor: 4.492
Authors: M Hickman; V Hope; T Brady; P Madden; S Jones; S Honor; G Holloway; F Ncube; J Parry Journal: J Viral Hepat Date: 2007-09 Impact factor: 3.728
Authors: Catherine S Todd; Abdullah M S Abed; Steffanie A Strathdee; Paul T Scott; Boulos A Botros; Naqibullah Safi; Kenneth C Earhart Journal: Emerg Infect Dis Date: 2007-09 Impact factor: 6.883
Authors: Márcia Alves Dias de Matos; Renata Carneiro Ferreira; Fabiana Perez Rodrigues; Tamíris Augusto Marinho; Carmen Luci Rodrigues Lopes; Antônia Carlos Magalhães Novais; Ana Rita Coimbra Motta-Castro; Sheila Araújo Teles; Francisco José Dutra Souto; Regina Maria Bringel Martins Journal: Mem Inst Oswaldo Cruz Date: 2013-05 Impact factor: 2.743
Authors: Catherine S Todd; Abdul Nasir; Mohammad Raza Stanekzai; Katja Fiekert; Heather L Sipsma; Steffanie A Strathdee; David Vlahov Journal: Int J Drug Policy Date: 2015-07-29
Authors: Catherine S Todd; Abdul Nasir; G Farooq Mansoor; Sayed M Sahibzada; Linda L Jagodzinski; Farzana Salimi; M Naim Khateri; Braden R Hale; R Vincent Barthel; Paul T Scott Journal: BMC Infect Dis Date: 2012-08-21 Impact factor: 3.090